Bharat Biotech Reports Results of Covaxin (BBV152) in P-II/III Trial for the Treatment of COVID-19
Shots:
- The P-II/III trial evaluate Covaxin on a two-dose schedule administered 28-days apart in 525 children aged 2 to 18yrs. at 6 clinical trial sites across India
- The results showed a robust neutralizing Ab response compared to previous P-III study, ≥93% reduction in severe disease along with favorable safety profile on medRXiv, strong immune response after 2nd dose, increased Abs titers against 3 viral antigens & no serious AEs were reported in any age groups
- Bharat Biotech plans to submit data from the P-III trial to a peer-reviewed scientific publication shortly. Under the recommendation by an independent committee, the data were submitted to the DCGI to support a pediatric indication
Ref: Bharat Biotech | Image: Bharat Biotech
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com